Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.
Demand for bioconjugates is increasing as more ADCs and other bioconjugates progress through clinical development towards commercialization. In response, Lonza is expanding its manufacturing network through two complementary investments: converting existing mid-scale bioconjugation manufacturing suites into a standardized single-use platform by 2027 and adding new large-scale commercial bioconjugation capacity which is expected to be operational from 2028.
Christian Seufert, Head of Advanced Synthesis, Lonza, commented: “As more ADCs and other bioconjugates advance towards commercialization, customers need confidence that manufacturing capacity can grow with their programs. Lonza’s investments in Visp reinforce our ambition to be the leading CDMO partner for integrated bioconjugation development and manufacturing solutions.”
The mid-scale bioconjugation manufacturing suites with 500 liter single-use capacity provide a flexible manufacturing environment within Lonza’s existing bioconjugation assets, supporting multiple products and programs. Scheduled for completion in 2027, the upgrade will add single-use equipment, chromatography capabilities and parallel manufacturing capacity to support faster campaign changeovers, more flexible planning and a broader range of ADC and bioconjugate programs.
The new large-scale bioconjugation facility is under construction at Lonza’s manufacturing complex in Visp. It will add three multiproduct suites for cytotoxic and non-cytotoxic products, with stainless-steel and single-use manufacturing at scales of up to 1,200 liters. Capacity is expected to be operational from 2028, supporting flexible, high-throughput commercial supply across customer programs providing security of supply and competitive Cost-of-Goods for ADCs to our customers.
The combined offering will give customers greater manufacturing flexibility, faster onboarding of new ADC programs and a scalable pathway from clinical development to high-volume commercial supply. By aligning adaptable multiproduct capacity with changing program needs, Lonza is strengthening its integrated bioconjugation offering and supporting customers as they advance their therapies towards commercialization.
